PMID: 26823859Jan 30, 2016Paper

B-cell lymphoma 2 rs17757541 C>G polymorphism was associated with an increased risk of coronary artery disease in a Chinese population

International Journal of Clinical and Experimental Pathology
Yang XuanZu-Hong Lu

Abstract

The goal of our study was to evaluate the genetic effects of sixteen single nucleotide polymorphisms (SNPs) in apoptosis-related genes on the development of coronary artery disease (CAD) through a case-control study. A total of 1979 individuals, including 826 CAD cases (aged 67.27 ± 10.26 years) and 1153 non-CAD controls (aged 59.13 ± 10.51 years), were enrolled into the study. The genotypes were determined using a custom-by-design 48-Plex SNPscanTM Kit. The results showed that the BCL2 rs17757541 C>G polymorphism was associated with increased risk of CAD in homozygote comparison and recessive genetic model. However, no association between the other fifteen SNPs and CAD risk was observed. Stratified analyses indicated a significantly increased risk of CAD associated with the BCL2 rs17757541 C>G polymorphism among males and younger patients. Therefore, the results indicated that there is a close correlation between the BCL2 rs17757541 C>G polymorphism and CAD, which suggests that this SNP site should be further studied as a potential biomarker for CAD.

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.